Drugs / TENIVAC
TENIVAC
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05077137 | Sep 2021 → Jul 2027 expected | melanoma | Duke University | Recruiting | No outcome recorded |
| Phase 1 | NCT02673255 | Aug 2016 → Jul 2019 | — | Biomat USA, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05294588 | Apr 2022 → Feb 2026 | gonorrhea | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT02097849 | Feb 2015 → May 2016 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06588530 | Nov 2024 → Jan 2025 | autoinflammatory syndrome, diphtheria, tetanus | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 4 | NCT01439165 | Nov 2011 → Dec 2015 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02193347 Background | Jan 2016 → Feb 2020 | brain glioma, primary brain neoplasm | Katy Peters, MD, PhD | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tenivac | “Tetanus and Diphtheria (Td) Vaccine, Manufacturer: Sanofi Pasteur (Tenivac), Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration:...” NCT02673255 ↗2“Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (TENIVAC) vaccine” NCT01439165 ↗ |
| Known as | tetanus diphtheria toxoids vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02097849 ↗ |
| Known as | Tetanus-Diphtheria Toxoid (Td) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02193347 ↗ |
| Known as | Tetanus-diptheria Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05294588 ↗ |
| Modality | Vaccine | “Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (TENIVAC) vaccine” NCT01439165 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT01439165 ↗ |